Notter Markus, Thomsen Andreas R, Nitsche Mirko, Hermann Robert M, Wolff Hendrik A, Habl Gregor, Münch Karin, Grosu Anca-L, Vaupel Peter
Department of Radiation Oncology, Lindenhofspital Bern, 3012 Bern, Switzerland.
Department of Radiation Oncology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.
Cancers (Basel). 2020 Mar 6;12(3):606. doi: 10.3390/cancers12030606.
Effective tumor control in patients suffering from unresectable locally recurrent breast cancer (LRBC) in pre-irradiated areas can be achieved by re-irradiation combined with superficial hyperthermia. Using this combined modality, total re-irradiation dose and toxicity can be significantly reduced compared to conventionally fractionated treatment schedules with total doses of 60-66 Gy. Applying contact-free, thermography-controlled water-filtered infrared-A superficial hyperthermia, immediately followed by hypofractionated re-irradiation, consisting of 4 Gy once per week up to a total dose of 20 Gy, resulted in high overall response rates even in large-sized tumors. Comparability of clinical data between different combined Hyperthermia (HT)/Radiotherapy (RT) treatment schedules is impeded by the highly individual characteristics of this disease. Tumor size, ranging from microscopic disease and small lesions to large-sized cancer en cuirasse, is described as one of the most important prognostic factors. However, in clinical studies and analyses of LRBC, tumor size has so far been reported in a very heterogeneous way. Therefore, we suggest a novel, simple and feasible size classification (rClasses 0-IV). Applying this classification for the evaluation of 201 patients with pre-irradiated LRBC allowed for a stratification into distinct prognostic groups.
对于先前接受过放疗区域出现不可切除的局部复发性乳腺癌(LRBC)患者,再程放疗联合浅表热疗可有效控制肿瘤。与总剂量为60 - 66Gy的传统分次治疗方案相比,采用这种联合治疗方式可显著降低再程放疗的总剂量和毒性。应用非接触式、热成像控制的水过滤红外A浅表热疗,随后立即进行大分割再程放疗,即每周一次给予4Gy,直至总剂量达20Gy,即便对于大体积肿瘤也能产生较高的总体缓解率。这种疾病的高度个体化特征阻碍了不同联合热疗(HT)/放疗(RT)治疗方案之间临床数据的可比性。肿瘤大小从微小病变、小病灶到巨大铠甲样癌不等,被认为是最重要的预后因素之一。然而,在LRBC的临床研究和分析中,迄今为止肿瘤大小的报告方式非常不一致。因此,我们提出一种新颖、简单且可行的大小分类方法(rClasses 0 - IV)。将此分类方法应用于201例先前接受过放疗的LRBC患者的评估,可将其分层为不同的预后组。